Repligen reports positive results from RG1068 Phase 3 study to improve MRI of the pancreas
Links shared publicly online about this topic.
- 440total visits
Repligen reports positive results from RG1068 Phase 3 study to improve MRI of the pancreas
View full resource at news-medical.net
Tags: Pancreatic Disease, Disease and Condition, Imaging Tests, Magnetic Resonance Imaging, Phase 3 Clinical Trial, disease, Safety
Most Recently Shared on March 14, 2011 at 5:21 pm By:
Repligen reports positive results from RG1068 Phase 3 study to improve MRI of the pancreas: Repligen Corporation... http://bit.ly/ecWGVz
Repligen Reports Positive Phase 3 Clinical Trial Results For RG1068 In Pancreatic Imaging
medicalnewstoday.com — “Repligen Corporation (NASDAQ: RGEN) reported positive top-line results from a Phase 3 study to evaluate the safety and efficacy of RG1068, synthetic human secretin, to improve magnetic resonance i” View full resource at medicalnewstoday.com
Most Recently Shared on March 16, 2011 at 7:05 am By:
MNT MRI / Ultrasound Health News
Repligen Reports Positive Phase 3 Clinical Trial Results For RG1068 In Pancreatic Imaging http://mnt.to/3Sj6 #mri #pet #ultrasound
Advertisement
